Journal
JOURNAL OF PHARMACOLOGICAL SCIENCES
Volume 132, Issue 2, Pages 115-121Publisher
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2016.10.002
Keywords
NMDA receptor; GluN2B/NR2B; Neuropsychiatric disorders; Developmental delay; Intellectual disability
Categories
Funding
- Eunice Kennedy Shriver National Institute of Child Health & Human Development [R01HD082373]
- National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454]
- National Institute of Neurological Disorders and Stroke [NS036654]
Ask authors/readers for more resources
The development of whole exome/genome sequencing technologies has given rise to an unprecedented volume of data linking patient genomic variability to brain disorder phenotypes. A surprising number of variants have been found in the N-methyl-D-aspartate receptor (NMDAR) gene family, with the GRIN2B gene encoding the GluN2B subunit being implicated in many cases of neurodevelopmental disorders, which are psychiatric conditions originating in childhood and include language, motor, and learning disorders, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), developmental delay, epilepsy, and schizophrenia. The GRIN2B gene plays a crucial role in normal neuronal development and is important for learning and memory. Mutations in human GRIN2B were distributed throughout the entire gene in a number of patients with various neuropsychiatric and developmental disorders. Studies that provide functional analysis of variants are still lacking, however current analysis of de novo variants that segregate with disease cases such as intellectual disability, developmental delay, ASD or epileptic encephalopathies reveal altered NMDAR function. Here, we summarize the current reports of disease-associated variants in GRIN2B from patients with multiple neurodevelopmental disorders, and discuss implications, highlighting the importance of functional analysis and precision medicine therapies. (C) 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available